Literature DB >> 15575245

Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol.

Masaharu Kataoka1, Toru Satoh, Tomohiro Manabe, Toshihisa Anzai, Tsutomu Yoshikawa, Hideo Mitamura, Satoshi Ogawa.   

Abstract

We report a 48-year-old woman with right heart failure due to primary pulmonary hypertension. Continuous infusion of epoprostenol (prostaglandin I2) for 1.5 years failed to control her condition, but she was later successfully treated with additional sildenafil for a few months. Her mean pulmonary artery pressure was originally 57 mmHg, increased to 62 mmHg with epoprostenol, and decreased to 45 mmHg with sildenafil. Additional sildenafil may be an effective and life-saving agent in patients with primary pulmonary hypertension who show a poor response to epoprostenol, which is considered to be very powerful medical treatment for the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15575245     DOI: 10.2169/internalmedicine.43.945

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke.

Authors:  Lian Li; Quan Jiang; Li Zhang; Guangliang Ding; Zheng Gang Zhang; Qingjiang Li; James R Ewing; Mei Lu; Swayamprava Panda; Karyn A Ledbetter; Polly A Whitton; Michael Chopp
Journal:  Brain Res       Date:  2006-12-26       Impact factor: 3.252

2.  Sildenafil-Induced Revascularization of Rat Hindlimb Involves Arteriogenesis through PI3K/AKT and eNOS Activation.

Authors:  Celine Baron-Menguy; Arnaud Bocquet; Alexis Richard; Anne-Laure Guihot; Bertrand Toutain; Pierre Pacaud; Celine Fassot; Gervaise Loirand; Daniel Henrion; Laurent Loufrani
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.